Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
About this trial
This is an interventional prevention trial for Hepatitis B focused on measuring hepatitis B vaccine, Heplisav-B, cirrhosis, chronic liver disease, 2 dose regimen, 3 dose regimen, non responder, poor responder, no response
Eligibility Criteria
Inclusion Criteria:
- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited.
Exclusion Criteria:
- Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
- Those who had previous exposure to hepatitis B.
- Post liver transplant patients.
- Less than 18 years old.
Sites / Locations
- Mercy Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
Cirrhosis, 3-dose regimen
Cirrhosis, 2-dose regimen
Non cirrhosis, 3-dose regimen
Non cirrhosis, 2-dose regimen
Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.